SBIR-STTR Award

Bacteria-related infection represents the most significant hurdle to normal wound healing resulting in >100,000 deaths in the United States each year. Due to the emergence of antibiotic resistant bacteria and the concomitant decrease in effective drug (i.e., antibiotic) development against such strains, the threat of life-threatening infections is ever increasing. Several small biotechnology companies are working towards the development of new, cost-effective wound treatments with widespread antibacterial efficacy. Unfortunately, many current approaches are complex, cost prohibitive, and only mildly effective against the most severe bacteria strains. Nitric oxide (NO) has garnered much attention as a therapeutic because of its role in blood pressure regulation (e.g., vasodilation), wound healing, and the immune response, particularly against bacteria. Current scientific knowledge regarding NO's role in immune system response and its proven antibacterial activity suggest that therapies based on NO release may represent a new paradigm for treating skin wounds. Novan, Inc. (Nitric Oxide Vehicles and Nanotechnology) was established in January 2006 to commercialize chemical strategies that safely and controllably deliver therapeutic concentrations of NO. The primary aim of this Phase I STTR proposal is to develop an antibacterial wound dressing based on NO-releasing silica nanoparticles that delivers effective concentrations of NO to the site of a wound. Our specific objectives include: 1) developing a topical formulation capable of controllably releasing NO at appropriate levels to treat infection and serve as a barrier to further colonization of an external wound site; and, 2) evaluating the broad-spectrum antibacterial activity of the NO-releasing nanoparticles against an extended set of gram negative and gram-positive bacteria. The nanoparticle synthesis and antibacterial testing will be a joint effort between Novan, Inc. and its partnering institution, the University of North Carolina at Chapel Hill. Cirrus Pharmaceuticals, Inc., a contract research organization in Durham, NC, will assist in the development of a polymeric wound dressing formulation to accommodate the nanoparticles. Both NO release stability and activity will be evaluated as a function of polymer composition. The goal in Phase I am to develop a NO-releasing wound barrier dressing with proven bactericidal activity.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
There Are No Thesaurus Terms On File For This Project.

Bacteria-related infection represents the most significant hurdle to normal wound healing resulting in >100,000 deaths in the United States each year. Due to the emergence of antibiotic resistant bacteria and the concomitant decrease in effective drug (i.e., antibiotic) development against such strains, the threat of life-threatening infections is ever increasing. Several small biotechnology companies are working towards the development of new, cost-effective wound treatments with widespread antibacterial efficacy. Unfortunately, many current approaches are complex, cost prohibitive, and only mildly effective against the most severe bacteria strains. Nitric oxide (NO) has garnered much attention as a therapeutic because of its role in blood pressure regulation (e.g., vasodilation), wound healing, and the immune response, particularly against bacteria. Current scientific knowledge regarding NO's role in immune system response and its proven antibacterial activity suggest that therapies based on NO release may represent a new paradigm for treating skin wounds. Novan, Inc. (Nitric Oxide Vehicles and Nanotechnology) was established in January 2006 to commercialize chemical strategies that safely and controllably deliver therapeutic concentrations of NO. The primary aim of this Phase I STTR proposal is to develop an antibacterial wound dressing based on NO-releasing silica nanoparticles that delivers effective concentrations of NO to the site of a wound. Our specific objectives include: 1) developing a topical formulation capable of controllably releasing NO at appropriate levels to treat infection and serve as a barrier to further colonization of an external wound site; and, 2) evaluating the broad-spectrum antibacterial activity of the NO-releasing nanoparticles against an extended set of gram negative and gram-positive bacteria. The nanoparticle synthesis and antibacterial testing will be a joint effort between Novan, Inc. and its partnering institution, the University of North Carolina at Chapel Hill. Cirrus Pharmaceuticals, Inc., a contract research organization in Durham, NC, will assist in the development of a polymeric wound dressing formulation to accommodate the nanoparticles. Both NO release stability and activity will be evaluated as a function of polymer composition. The goal in Phase I am to develop a NO-releasing wound barrier dressing with proven bactericidal activity.

Thesaurus Terms:
Animal Model; Animal Models And Related Studies; Anti-Bacterial Agents; Antibacterial Agents; Antibiotic Agents; Antibiotic Drugs; Antibiotic Resistance; Antibiotics; Articulation; Attention; Bp Control; Bacteria; Biotechnology; Burn Injury; Burns; Caring; Cessation Of Life; Chemicals; Clinical; Common Rat Strains; Complex; Cristobalite; Death; Dermal; Development; Diabetic Foot Ulcer; Dressing; Drug Formulations; Drugs; Endogenous Nitrate Vasodilator; Endothelium-Derived Relaxing Factor; Fibroblasts; Foot Ulcer, Diabetic; Formulation; Formulations, Drug; Funding; Gases; Goals; Gram-Positive Bacteria; Hydrogen Oxide; Immune Response; Immune System; In Vitro; Infection; Institution; Joints; Kinetic; Kinetics; Knowledge; Life; Lytotoxicity; Mrsa; Mammals, Rats; Marketing; Measures; Medical; Medication; Methicillin Resistant S. Aureus; Methicillin Resistant Staphylococcus Aureus; Method Loinc Axis 6; Methodology; Miscellaneous Antibiotic; Mononitrogen Monoxide; Nanoscale Science; Nanotechnology; Nitric Oxide; Nitric Oxide, Endothelium-Derived; Nitrogen Monoxide; Nitrogen Protoxide; Nitrogen Oxide; North Carolina; Ostamer; Otomy; Pellethane; Permeability; Pharmaceutic Preparations; Pharmaceutical Agent; Pharmaceutical Preparations; Pharmaceuticals; Pharmacologic Substance; Pharmacological Substance; Phase; Polyisocyanates; Polymers; Polyurethanes; Property; Property, Loinc Axis 2; Protocol; Protocols Documentation; Rat; Rattus; Research; Research Contracts; Resistance To Antibiotics; Resistance, Antibiotic; Resistant To Antibiotics; Role; Sttr; Sand; Silica; Silicon Dioxide; Site; Skin; Small Business Technology Transfer Research; Sterile Coverings; Surgical Incisions; Testing; Therapeutic; Tridymite; United States; Universities; Vasodilatation; Vasodilation; Vasorelaxation; Water; Work; Wound Healing; Wound Repair; Anti-Bacterial; Antibacterial; Antibiotic Resistant; Bactericidal; Bactericide; Base; Blood Pressure Control; Blood Pressure Homeostasis; Blood Pressure Regulation; Body System, Allergic/Immunologic; Controlled Release; Cost; Cytotoxicity; Design; Designing; Drug/Agent; Endothelial Cell Derived Relaxing Factor; Experiment; Experimental Research; Experimental Study; Host Response; Immunoresponse; Incision; Methicillin Resistant Staphylococcus Aureus (Organism); Model Organism; Nano Particle; Nano Scale Science; Nano Tech; Nano Technology; Nanoparticle; Nanotech; Organ System, Allergic/Immunologic; Preclinical Evaluation; Research Study; Response; Scaffold; Scaffolding; Social Role; Success; Tissue Repair; Uptake; Wound